When Boston Scientific Corporation (BSX) announced Thursday that it's buying thrombectomy specialist Penumbra Inc. (PEN), the market reaction split predictably down the middle. Penumbra shares surged while Boston Scientific stock declined as investors weighed the growth opportunity against the near-term costs of digesting a $14.5 billion acquisition.
The timing wasn't accidental. Penumbra sweetened the deal announcement with preliminary fourth-quarter results that exceeded expectations, reinforcing why Boston Scientific is willing to write such a large check to enter new segments of the vascular space.
What Boston Scientific Is Buying
The transaction values Penumbra at $374 per share, with shareholders able to choose between cash or Boston Scientific stock. After proration, the mix works out to roughly 73% cash and 27% equity. That puts the enterprise value around $14.5 billion for a company that's been building a strong position in thrombectomy devices used to remove blood clots.
Boston Scientific CEO Mike Mahoney framed it as an expansion play: "Penumbra is a well-established company with an experienced, high-performing team and this acquisition offers Boston Scientific an opportunity to enter new, fast-growing segments within the vascular space."
Penumbra CEO Adam Elsesser emphasized the strategic fit, noting his company's focus on innovation for complex conditions aligns with Boston Scientific's broader strategy. He also confirmed he'll be receiving Boston Scientific shares and joining its board after the deal closes, signaling confidence in the combined entity's prospects.
The Numbers Behind the Premium
Those preliminary Q4 figures help explain the valuation. Penumbra reported fourth-quarter 2025 revenue between $383.0 million and $384.8 million, representing year-over-year growth of approximately 21% to 22%. Strip out China from the equation, and growth accelerates to roughly 23% to 24%.
For the full year 2025, revenue hit approximately $1.40 billion, up about 17% from the prior year. On an ex-China basis, that growth rate jumped to nearly 25%. Profitability metrics remained solid, with gross margin approaching 68% in the quarter and just over 67% for the full year. Operating income landed in the $57 million to $60 million range for Q4 and approximately $187 million to $190 million for the year, translating to operating margins in the mid-teens.
How Boston Scientific Plans to Pay
Boston Scientific will fund the roughly $11 billion cash portion through a combination of existing cash and new debt. As of September 30, 2025, the company held $1.275 billion in cash and cash equivalents, so borrowing will play a significant role in financing this acquisition.
The company is projecting adjusted earnings dilution of 6 cents to 8 cents per share in the first full year after closing. By year two, results should trend toward neutral to accretive, with more meaningful accretion expected in subsequent years as the integration progresses and synergies materialize.
The Bigger Picture
The transaction is expected to close sometime in 2026, assuming Penumbra shareholders approve the deal and regulators sign off on the customary conditions. It's another example of ongoing consolidation in the medical devices sector, where companies are looking to expand their portfolios and enter adjacent markets through strategic acquisitions rather than building capabilities from scratch.
Price Action: Penumbra shares jumped 17.29% to $353.00 during premarket trading on Thursday, hitting a new 52-week high. Boston Scientific shares fell 6.52% as investors processed the near-term dilution and integration challenges ahead.
